Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 14 cyclopia sequence 7 Neoplasms 7 Prostatic Neoplasms 6 Polycystic Ovary Syndrome 5 Fatigue 5 Lung Neoplasms 4 Head and Neck Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Pain 3 Obesity 3 Neoplasm Metastasis 3 Vomiting 2 Urinary Bladder Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pancreatic Neoplasms 2 Neoplasms, Plasma Cell 2 Nausea 2 Multiple Myeloma 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Insulin Resistance 2 Infertility 2 Hyperandrogenism 2 Depression 2 Burkitt Lymphoma 2 Weight Loss 1 Vitamin D Deficiency 1 Tobacco Use Cessation 1

Interventions

Nivolumab 146 Ipilimumab 137 pembrolizumab 122 Cyclophosphamide 78 Interleukin-2 69 aldesleukin 63 Temozolomide 46 trametinib 37 Radiosurgery 37 Vemurafenib 36 fludarabine 34 Biopsy 34 dabrafenib 33 Radiotherapy 33 Blood Specimen Collection 31 fludarabine phosphate 30 sargramostim 27 Bevacizumab 27 Introns 23 Dacarbazine 22 Magnetic Resonance Spectroscopy 21 Specimen Handling 20 CTLA-4 Antigen 20 encorafenib 19 cobimetinib 19 binimetinib 19 Paclitaxel 19 Granulocyte-Macrophage Colony-Stimulating Factor 19 Cisplatin 17 incomplete Freund's adjuvant 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Melanoma × Sugars × Clear all

NCT04899921 2024-03-26

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Dana-Farber Cancer Institute

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡